Oncology

Andrew E. Esch, MD, MBA, discusses the need for systemic reforms to support pharmacist-led medication optimization in palliative and community-based care.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

Pharmacy leaders from Cone Health discuss how robotic compounding technologies have improved safety, accuracy, and reliability in hazardous and sterile medication preparation across oncology and acute care settings.

The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.

Manish Agrawal, MD, discusses the implementation of psilocybin-assisted therapy in a community cancer setting, highlighting its potential to provide sustained relief from depression and anxiety and its significant efficacy advantage over selective serotonin reuptake inhibitors for patients with cancer.

Obecabtagene autoleucel shows promising efficacy and safety in treating relapsed/refractory B-ALL, benefiting patients of all ages, including older adults.

Gianni Scappaticci, PharmD, BCOP, outlines a personalized, evidence-based approach to managing steroid-refractory chronic graft-versus-host disease (cGVHD) in a post–haploidentical transplant patient, highlighting the rationale for using ruxolitinib, belumosudil, or their combination based on disease progression and fibrotic features.

FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.

Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for routine screening.

Ropeginterferon alfa-2b shows promising results in treating preprimary myelofibrosis, enhancing clinical responses and safety in patients.

Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.

Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.

Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-vs-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.

INCB057643 shows promise in treating myelofibrosis, enhancing anemia and symptom relief.

The agent continues to show promising clinical benefit despite being pulled from the market in 2023.

The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.

Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with a reduced incidence of cancer over time, although more research is necessary.

Psychedelic treatments may ease cancer distress at various stages of the care journey.

Pharmacy experts share the benefits of the annual Oncology Pharmacists Connect meeting.

Combining benmelstobart and anlotinib shows promise for patients with squamous non-small cell lung cancer.

Kevin Chen, PharmD, MS, BCOP, CPP, highlighted key thoracic cancer advances from the 2025 ASCO Annual Meeting.

Jaume Capdevila, MD, PhD, discusses phase 1 data showing promising efficacy and manageable safety for obrixtamig in patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas, along with ongoing trials evaluating its use in both monotherapy and combination settings.

Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing.